Given the numerous randomized clinical trials (RCTs) of antidopaminergic agents for schizophrenia, meta-analyses can help compare their efficacy and safety/tolerability. Because many medications have never been directly compared, network meta-analyses (NMAs) using direct and indirect effect size estimates via common comparators have been introduced. Because “transitivity” (eg, similar populations, treatment, and measurement approaches) is required, changes in patient, illness, treatment, trial design/conduct characteristics, and increasing placebo effects in schizophrenia trials1 challenge the underlying assumptions of NMAs.